Company / Shareholders' Equity
Editas Medicine, Inc. Shareholders' Equity History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$134.3M
FY2025
5-year range
$134.3M / $553.6M
FY2021-FY2025
Trend
-61.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $554M to $134M over the past 2 years.
Based on SEC 10-K filings.
$134M in FY2025 with a 5-year CAGR of -10.7%.
Declined from $554M to $134M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -30.1%
- 5-Year CAGR
- -10.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -10.7%, indicating a declining trend.
- In FY2025, shareholders' equity decreased 61.5% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $134.3M | -61.5% |
| FY2024 | $349.1M | -36.9% |
| FY2023 | $553.6M | +40.7% |
| FY2022 | $393.6M | +50.0% |
| FY2021 | $262.4M | +11.1% |
| FY2020 | $236.2M | +13.5% |
| FY2019 | $208.1M | +54.6% |
| FY2018 | $134.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026